A Two Part Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Renal Safety, Tolerability and Pharmacokinetics of LHW090 in Patients With Moderately Impaired Renal Function on Angiotensin Receptor Blockers

Trial Profile

A Two Part Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Renal Safety, Tolerability and Pharmacokinetics of LHW090 in Patients With Moderately Impaired Renal Function on Angiotensin Receptor Blockers

Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Jul 2017

At a glance

  • Drugs LHW 090 (Primary)
  • Indications Kidney disorders
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 21 Mar 2017 Planned End Date changed from 28 Feb 2018 to 2 Apr 2018.
    • 21 Mar 2017 Planned primary completion date changed from 28 Feb 2018 to 2 Apr 2018.
    • 21 Mar 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top